H. Lundbeck A/S (VIE:LUNA)

Austria flag Austria · Delayed Price · Currency is EUR
4.585
+0.025 (0.55%)
Last updated: Mar 4, 2026, 11:00 AM CET
5.28%
Market Cap 4.94B
Revenue (ttm) 3.30B
Net Income (ttm) 427.40M
Shares Out n/a
EPS (ttm) 0.43
PE Ratio 11.55
Forward PE 6.15
Dividend 0.13 (2.78%)
Ex-Dividend Date Mar 27, 2025
Volume n/a
Average Volume 136
Open 4.575
Previous Close 4.560
Day's Range 4.575 - 4.585
52-Week Range 3.125 - 5.320
Beta n/a
RSI 38.53
Earnings Date Feb 4, 2026

About H. Lundbeck

H. Lundbeck A/S engages in the research, development, manufacturing, and commercializing pharmaceuticals for the treatment of psychiatric and neurological disorders in Europe, United States, and internationally. The company offers Abilify Maintena/ Abilify Asimtufii for schizophrenia and bipolar I disorder in adults; Brintellix/Trintellix to treat depressive disorders; Rexulti/Rxulti to treat major depressive disorder and schizophrenia; Vyepti for migraine prevention; and Cipralex/Lexapro for depression. It also provides Northera for symptomati... [Read more]

Industry Pharmaceutical Preparations
Founded 1915
Employees 5,039
Stock Exchange Vienna Stock Exchange
Ticker Symbol LUNA
Full Company Profile

Financial Performance

In 2025, H. Lundbeck's revenue was 24.63 billion, an increase of 11.93% compared to the previous year's 22.00 billion. Earnings were 3.19 billion, an increase of 1.56%.

Financial numbers in DKK Financial Statements

News

There is no news available yet.